About the Generic Drugs Market
Generic drugs have the same chemical formula, dosage form, potency, route of administration, quality, and intended use as that of patented branded drugs. They cost 80%-85% lesser than their branded counterparts and are available soon after the patent expiries of original drugs. However, they are similar to original drugs in terms of safety, quality, and effectiveness. Manufacturers need to apply for an Abbreviated New Drug Application (ANDA) approval to receive approval of generics.
Technavio’s analysts forecast the global generic drugs market to grow at a CAGR of 10.53% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global generic drugs market for 2016-2020. To calculate the market size, it considers revenue generated from the sales of simple generics, super generics, and biosimilars.
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA
Technavio's report, Global Generic Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• Teva Pharmaceuticals
• Sandoz
• Allergan
• Mylan
• Sun Pharmaceuticals
• STADA Arzneimittel
Other prominent vendors
• Abbott
• Amgen
• Apotex
• Aspen
• AstraZeneca
• Aurobindo Pharma
• Baxter
• Berlin-Chemie
• Biocon
• Biogen
• Boehringer Ingelheim
• Celltrion
• Cipla
• Coherus Biosciences
• Dr. Reddy's Laboratory
• Daiichi Sankyo
• Eli Lilly
• Emcure Pharmaceuticals
• Eurofarma Laboratories
• Gedeon Richter
• Gilead Sciences
• GlaxoSmithKline
• Hospira
• Impax
• InnoPharma
• Intas Pharmaceuticals
• Jannsen
• Lupin
• Merck
• Mitsubishi Tanabe Pharma
• Momenta Pharmaceuticals
• Natco Pharma
• Nexus Pharmaceuticals
• Novo Nordisk
• Orchid Chemicals & Pharmaceuticals
• Parenteral Drugs India
• Par Pharmaceutical
• Pfizer
• Piramal (Abbott Laboratories)
• Roche Holdings
• Sanofi
• Synthon
• Towa
• Valeant Pharmaceuticals
• Zentiva
• Zhejiang Chira Medicine Chemicals
• Zhejiang Hisun Pharmaceutical
• Zydus Cadila Healthcare
Market driver
• Patent expiry of top-selling drugs
• For a full, detailed list, view our report
Market challenge
• Threat of counterfeit drugs
• For a full, detailed list, view our report
Market trend
• Outsourcing of drug development activities
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
PART 01: Executive summary
Highlights
PART 02: Scope of the report
Market overview
Top-vendor offerings
PART 03: Market research methodology
Research methodology
Economic indicators
PART 04: Introduction
Key market highlights
PART 05: Overview of generics
Generic drugs industry
Comparison between generic drugs and branded drugs
PART 06: Key leading countries
US
China
India
PART 07: Global pharmaceutical market
Market overview
Market size and forecast
PART 08: Market landscape
Market overview
Market size and forecast
Five forces analysis
PART 09: Market segmentation by category
Simple generics
Super generics
Biosimilars
PART 10: Market segmentation by therapeutic application
PART 11: Geographical segmentation
Global generic drugs market by geographical segmentation 2015-2020
Generic drugs market in Americas
Generic drugs market in APAC
Generic drugs market in EMEA
PART 12: Market drivers
Patent expiry of top-selling drugs
Growing acceptance of generic medicines
Increasing demand in emerging markets
Social and private health insurance in emerging markets
Increasing prevalence of diseases
PART 13: Impact of drivers
PART 14: Market challenges
Adverse effects
Stringent regulations
Threat of counterfeit drugs
Intense competition among vendors
PART 15: Impact of drivers and challenges
PART 16: Market trends
M&A
Outsourcing of drug development
Strategic alliances
PART 17: Vendor landscape
Competitive scenario
Market share analysis 2015
Teva Pharmaceuticals
Sandoz
Allergan
Mylan
Sun Pharmaceuticals
STADA Arzneimittel
Other prominent vendors
PART 18: Appendix
List of abbreviations
PART 19: Explore Technavio
List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Advantages and features of generic drugs
Exhibit 03: Value chain of generic pharmaceuticals
Exhibit 04: Regulatory bodies and associations for generic drugs in US and Europe
Exhibit 05: Types of drug application
Exhibit 06: Difference between unbranded, branded, and company-branded generics
Exhibit 07: Comparison between generic and branded drugs
Exhibit 08: Key leading countries in the global generic drugs market
Exhibit 09: Major drivers, challenges, and trends in generic drugs market in US
Exhibit 10: Major drivers, challenges, and trends in generic drugs market in China
Exhibit 11: Major drivers, challenges, and trends in generic drugs market in India
Exhibit 12: Global pharmaceutical market 2015-2020 ($ trillions)
Exhibit 13: Drivers, challenges, and trends in global pharmaceutical market
Exhibit 14: Global pharmaceutical and generic drugs market 2015 ($ billions)
Exhibit 15: Global generic drugs market 2015-2020 ($ billions)
Exhibit 16: Distribution of global medicine spending 2015
Exhibit 17: Five forces analysis
Exhibit 18: Global generic drugs market segmentation by category
Exhibit 19: Global biosimilars market 2015-2020 ($ billions)
Exhibit 20: Global generic drugs market segmentation by therapeutic application
Exhibit 21: Global generic drugs market segmentation by therapeutic application 2015
Exhibit 22: Global generic drugs market by geographical segmentation 2015
Exhibit 23: Global generic drugs market revenue by geographical segmentation 2015-2020 ($ billions)
Exhibit 24: Generic drugs market in Americas 2015-2020 ($ billions)
Exhibit 25: Generic drugs market in Americas by country 2015
Exhibit 26: Distribution of medicine spending in North America 2014
Exhibit 27: Distribution of medicine spending in Central and South America 2014
Exhibit 28: Generic drugs market in US 2015-2020 ($ billions)
Exhibit 29: Overview of generic drugs market in US
Exhibit 30: Regulations in US generic drugs market
Exhibit 31: Generic drugs market in APAC 2015-2020 ($ billions)
Exhibit 32: Distribution of medicine spending in APAC 2015
Exhibit 33: Generic drugs market in APAC by country 2015
Exhibit 34: Generic drugs market in China 2015-2020 ($ billions)
Exhibit 35: Generic drugs market in China 2015-2020 ($ billions)
Exhibit 36: Generic drugs market in India 2015-2020 ($ billions)
Exhibit 37: Generic drugs market in India 2015-2020 ($ billions)
Exhibit 38: Regulation in Indian generic drugs market
Exhibit 39: Generic drugs market in Japan 2015-2020 ($ billions)
Exhibit 40: YoY revenue and growth of the global generics drugs market by geography 2015-2020 ($ billions)
Exhibit 41: Generic drugs market in EMEA 2015-2020 ($ billions)
Exhibit 42: Distribution of medicine spending in Africa and Middle East 2015
Exhibit 43: Generic drugs market in Europe 2015-2020 ($ billions)
Exhibit 44: Overview of generic drugs market in Europe
Exhibit 45: Regulations in generic drugs market in Europe
Exhibit 46: Distribution of medicine spending in Europe 2014
Exhibit 47: Generic drugs market in Europe by country 2015
Exhibit 48: Generic drugs market in Germany 2015-2020 ($ billions)
Exhibit 49: Generic drugs market in the UK 2015-2020 ($ billions)
Exhibit 50: Generic drugs market in France 2015-2020 ($ billions)
Exhibit 51: Generic drugs market in Spain 2015-2020 ($ billions)
Exhibit 52: Generic drugs market in Italy 2015-2020 ($ billions)
Exhibit 53: Patent expiry of branded drugs by 2020
Exhibit 54: Impact of drivers
Exhibit 55: Impact of drivers and challenges
Exhibit 56: Global generic drugs market share analysis 2015
Exhibit 57: Top-10 global generic drug manufacturers by market share 2014
Exhibit 58: Teva Pharmaceuticals: Business segmentation by revenue 2014
Exhibit 59: Teva Pharmaceuticals: YoY growth rate and revenue of generic medicines segment 2012-2014 ($ billions)
Exhibit 60: Teva Pharmaceuticals: Geographic segmentation by revenue 2014 (generic medicines segment)
Exhibit 61: Teva Pharmaceuticals: YoY growth rate and revenue of Copaxone 2012-2014 ($ billions)
Exhibit 62: Teva Pharmaceuticals: YoY growth rate and revenue of Azilect 2012-2014 ($ millions)
Exhibit 63: Teva Pharmaceuticals: SWOT analysis
Exhibit 64: Sandoz: Business segmentation by revenue 2014
Exhibit 65: Sandoz: YoY revenue of retail generics segments 2013-2014 ($ billions)
Exhibit 66: Sandoz: SWOT analysis
Exhibit 67: Allergan: Business segmentation by revenue 2014
Exhibit 68: Allergan: YoY growth rate and revenue of North American generics and international segment 2012-2014 ($ billions)
Exhibit 69: Allergan: Geographic segmentation by revenue 2014 (North American generics and international segment)
Exhibit 70: Allergan: YoY revenue of Lo Loestrin Fe 2013-2014 ($ millions)
Exhibit 71: Allergan: SWOT analysis
Exhibit 72: Mylan: Business segmentation 2014 by revenue
Exhibit 73: Mylan: YoY growth rate and revenue of generics segment 2012-2014 ($ billion)
Exhibit 74: Mylan: Geographical segmentation by revenue 2014 (generics segment)
Exhibit 75: Mylan: SWOTS analysis
Exhibit 76: Sun Pharmaceuticals: Business segmentation by revenue 2014
Exhibit 77: Sun Pharmaceuticals: Geographical segmentation by revenue 2014
Exhibit 78: Sun Pharmaceuticals: SWOT analysis
Exhibit 79: STADA Arzneimittel: Business segmentation by revenue 2014
Exhibit 80: STADA Arzneimittel: YoY growth rate and revenue of generics segment 2012-2014 ($ billions)
Exhibit 81: STADA Arzneimittel: Geographical segmentation by revenue 2014 (generics segment)
Exhibit 82: STADA Arzneimittel: YoY growth rate and revenue of Omeprazole 2012-2014 ($ millions)
Exhibit 83: STADA Arzneimittel: YoY growth rate and revenue of Diclofenac 2012-2014 ($ millions)
Exhibit 84: STADA Arzneimittel: YoY revenue of Tilidine 2013-2014 ($ millions)
Exhibit 85: STADA Arzneimittel: YoY growth rate and revenue of Phospholipide 2013-2014 ($ millions)
Exhibit 86: STADA Arzneimittel: SWOT analysis
